Do you put weight back on after stopping weight loss injections?

Why does weight come back when you stop?

GLP-1 and dual GIP/GLP-1 medicines work by mimicking gut hormones that signal fullness, slow gastric emptying and dampen appetite. While you take them, eating less feels natural. Stop taking them, and those hormone signals fade within days to weeks. The result is that appetite returns (often sharply) to something close to where it was before treatment started.

This is not a sign of failure or lack of willpower. Obesity is a chronic condition with a strong biological basis, and the medicines address a physiological gap. Removing them re-opens that gap. The NHS explains this clearly in its guidance on weight-management medicines: the medicines treat the condition while they are taken, much like blood-pressure medication treats hypertension. The NHS medicines page for tirzepatide notes that weight management requires ongoing effort alongside any treatment.

A second factor is the body's adaptive response to weight loss. Resting metabolic rate tends to drop as body mass falls, meaning the number of calories needed to maintain the lower weight is smaller than before. Once appetite rebounds and intake rises, the body is primed to store more efficiently. This combination of increased hunger and reduced baseline energy expenditure is why regain can feel rapid.

How much weight do people typically regain after stopping?

The trial data is sobering. In a follow-up study after the STEP 1 semaglutide trial (published in the New England Journal of Medicine), participants who had lost around 15% of body weight during active treatment regained roughly two-thirds of that within a year of stopping, even while maintaining lifestyle support. Tirzepatide trials show a similar pattern in extension analyses.

That does not mean all progress disappears. Some participants retained meaningful reductions compared with baseline even at two years post-treatment. The people who maintained more were generally those who sustained higher physical activity levels and made durable changes to dietary patterns during treatment — not those who simply relied on the medicine and returned to prior habits the moment it stopped.

If you are curious what realistic before-and-after trajectories look like across the treatment period itself, the weight loss injections before and after page covers the evidence in more detail. The short version: losses during treatment are real and clinically significant; the question of what happens next depends heavily on what comes after.

Does stopping versus pausing make a difference?

There is a practical distinction worth understanding. A full stop, with no plan to restart, is different from a planned pause, say, for surgery, pregnancy planning, or a period when supply is interrupted. In the case of a pause, clinical evidence suggests losses can be partially preserved if the pause is short and the medicine is restarted promptly under prescriber guidance. Longer gaps tend to produce more pronounced regain before the medicine has time to re-establish its effect.

Planned pauses before pregnancy are a separate conversation: GLP-1 medicines are not recommended during pregnancy or breastfeeding, and the MHRA advises stopping in advance of trying to conceive. The weight loss injections after pregnancy page covers the timing and what to discuss with your prescriber. For surgical procedures, NHS England guidance notes that your anaesthetist should be told you are taking a GLP-1 medicine well before any procedure.

None of this means stopping is always the wrong decision. Some people reach a point where lifestyle changes are robust enough to sustain most of their progress. Others find that long-term treatment is the right answer clinically. That assessment belongs in a consultation with a prescriber who knows your full history.

What actually helps reduce regain if you do stop?

The evidence points consistently to a few factors. Protein intake matters: keeping it adequate preserves lean muscle mass during weight loss and helps regulate appetite after stopping. Strength-based activity has a similar effect on muscle and metabolic rate. Sleep quality and stress management affect hunger hormones independently of the medicine. None of these are trivial to sustain, which is why clinical guidance increasingly treats obesity as a long-term condition requiring long-term management rather than a one-off course of treatment.

It is worth knowing what ongoing clinical support looks like in practice. At nume, every repeat order is clinically re-reviewed by a GPhC-registered prescriber, not processed automatically, so conversations about whether to continue, reduce dose, or plan a structured stop happen before each dispensing, not as an afterthought. If you have questions about the cost of long-term treatment and what is included, the treatment overview page sets out what a single transparent price covers, including guidance on where to put weight loss injections so you can feel confident using them correctly from the start. For people earlier in the decision-making process, reading about the evidence on weight gain after stopping in more depth may help frame the conversation with your prescriber.

The pen itself arrives in plain, unbranded packaging via DPD with a tracking link, practical to know, but the more important point is what happens before it ships: a real prescriber has read your consultation answers and made a clinical call. That ongoing relationship is the thing that shapes outcomes over time. If you are still weighing up your options, reading about the trending weight loss injection that many patients are currently asking about may help you go into that conversation better informed. Check your eligibility and start that conversation via the free consultation.